Search clinical trials for: BNT113

Total 2 results

University of Southampton
BioNTech SE

Completed

HARE-40: HPV Anti-CD40 RNA vaccinE (HARE-40)

Unknown Primary Tumors | Head and Neck Neoplasm | Cervical Neoplasm | Penile Neoplasms Malignant | Human Papilloma Virus Related Carcinoma

United Kingdom
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden

3

Subscribe